JPS6363067B2 - - Google Patents
Info
- Publication number
- JPS6363067B2 JPS6363067B2 JP56039549A JP3954981A JPS6363067B2 JP S6363067 B2 JPS6363067 B2 JP S6363067B2 JP 56039549 A JP56039549 A JP 56039549A JP 3954981 A JP3954981 A JP 3954981A JP S6363067 B2 JPS6363067 B2 JP S6363067B2
- Authority
- JP
- Japan
- Prior art keywords
- dna
- cells
- virus
- restriction enzyme
- identifying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 108020004414 DNA Proteins 0.000 claims description 68
- 210000004027 cell Anatomy 0.000 claims description 64
- 241000700605 Viruses Species 0.000 claims description 50
- 108091008146 restriction endonucleases Proteins 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 37
- 238000003776 cleavage reaction Methods 0.000 claims description 28
- 230000007017 scission Effects 0.000 claims description 28
- 108020005202 Viral DNA Proteins 0.000 claims description 13
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 claims description 11
- 241000450599 DNA viruses Species 0.000 claims description 4
- 230000000120 cytopathologic effect Effects 0.000 claims description 4
- 238000001962 electrophoresis Methods 0.000 claims description 4
- 108010076804 DNA Restriction Enzymes Proteins 0.000 claims description 3
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 claims description 3
- 229960005542 ethidium bromide Drugs 0.000 claims description 3
- 230000001605 fetal effect Effects 0.000 claims description 3
- 210000003292 kidney cell Anatomy 0.000 claims description 2
- 239000012264 purified product Substances 0.000 claims 1
- 238000010186 staining Methods 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 description 18
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 108091092356 cellular DNA Proteins 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000007018 DNA scission Effects 0.000 description 5
- 241000701096 Human adenovirus 7 Species 0.000 description 5
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 206010001257 Adenoviral conjunctivitis Diseases 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- -1 BamH Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 2
- 241000193096 Human adenovirus B3 Species 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- XNCSCQSQSGDGES-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]propyl-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(O)=O XNCSCQSQSGDGES-UHFFFAOYSA-N 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000696272 Gull adenovirus Species 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000037950 acute febrile pharyngitis Diseases 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000021373 epidemic keratoconjunctivitis Diseases 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000001738 isopycnic centrifugation Methods 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000001369 pharyngoconjunctival fever Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 201000006476 shipyard eye Diseases 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
本発明はウイルス血清型の型別同定法に関す
る。更に詳しくは、本発明は、DNAウイルス感
染細胞の全DNAの制限酵素切断パターンから、
ウイルス血清型の型別を同定する方法に関するも
のである。
ウイルスに基因する疾病の適切な診断、治療及
び予防のためには、ウイルスの血清型を適確に同
定する必要がある。例えば、アデノウイルス群ウ
イルスは、急性熱性咽頭炎、急性気道疾患、咽頭
結膜熱、流行性角結膜炎、百日咳様症候群などの
疾患の原因ウイルスであるが、このウイルス群に
は確認された31の血清型があり(ウイルスDNA
の塩基配列の相同性からA〜Eの5つの群に分け
られる)、疾患の適切な診断、治療及び予防のた
めには、ウイルス血清型の適確な同定を行なう必
要がある。
従来、ウイルス、例えば、アデノウイルスの血
清型の同定に関しては、補体結合反応及び螢光抗
体法がアデノウイルスの共通の抗原を検出する目
的で用いられ、一方、赤血球凝集阻止反応及び中
和反応が型別の決定に用いられてきた。しかしな
がら、赤血球凝集阻止反応及び中和反応による同
定においては、型間で交叉反応を示す場合があ
り、従つて、正確度に疑問のある場合があつた。
また各型の抗血清を準備しなければならず簡便性
の点でも問題があつた。
最近、ヘルペスウイルスDNAを制限酵素で切
断し、その切断パターンから血清型を同定する方
法が紹介されている(ザ・ジヤーナル・オブ・イ
ンフエクシヤス・デイジーズ(The Journal of
Infectious Diseases)第138巻、第4号、第488
−498頁(1978年))。しかしながら、この方法に
おいては、ヘルペスウイルスを単離精製して用い
ており、ウイルスの精製には多量の感染細胞が必
要であり、かつ複雑な手法が要求され、多大の時
間と労力を要するので、この方法は特に診断、治
療上は実用的に問題があつた。
本発明者らは、DNAウイルスの血清型を少量
の感染細胞を用いて簡単にかつ正確に同定する方
法に関し鋭意研究を行なつた結果、DNAウイル
ス感染細胞から全DNAを抽出し、これをその
まゝ(ウイルスDNAと細胞DNAを分離すること
なく)制限酵素で切断し切断パターンを形成させ
ると、細胞DNAに影響されることなくウイルス
DNAの切断パターンが明瞭に判別でき、簡単か
つ正確にその血清型を同定できることを知見し本
発明に到達した。
即ち、本発明は、DNAウイルスをDNAウイル
ス感受性細胞に感染させ、この感染細胞を培養後
感染細胞の全DNAを抽出・精製し、次いでウイ
ルスDNAと細胞DNAを分離することなく前記抽
出精製した全DNAを制限酵素で切断し、その切
断パターンを、血清型が既知のDNAウイルスの
DNAの制限酵素切断パターンと比較することを
特徴とする、ウイルス血清型の型別同定法であ
る。
本発明の方法を使つて、血清型の型別を同定で
きるDNAウイルスは特に制限されるものではな
く、その原理はいずれのDNAウイルスに対して
も応用できるが、アデノウイルス群ウイルスやヘ
ルペス群ウイルスには特に好適に適用できる。
DNAウイルス感受性細胞としては、DNAウイ
ルスに感染されかてそれを増殖させうるものであ
れば何でもよいが、アデノウイルス群ウイルスの
場合にはKB細胞、Hela細胞、ヒト胎児腎細胞が
好ましく、ヘルペス群ウイルスの場合にはHep
細胞、Hela細胞又はVelo細胞が好ましく、更に
ヘルペス群ウイルスの中の水痘ウイルスの場合に
はヒト胎児肺細胞、繊維芽細胞が好ましい。
DNAウイルスを感染させた感染細胞は公知の
方法で培養できる。適当は培地としては、例え
ば、5%子牛血清を含むイーグルミニマムエツセ
ンシヤルミデイアム(MEM)がある。培養条件
は、例えば、5%CO2通気下、37℃で1〜7日で
十分である。感染細胞が破壊されウイルス粒子が
飛び出すと、その後の処理に不便であるから培養
は、明瞭な細胞変性効果が発現した段階で止める
のが最も好ましい。その後、かかる感染細胞から
感染細胞の全DNA、即ちウイルスDNAと細胞
DNAを抽出・精製する。DNAの抽出・精製法は
特に限定されるものではないが、以下のフエノー
ル法とジエチルピロカーボネート(DEPC)法が
好ましい。後者は、特に少量の細胞を処理する場
合に適している。
(1) 本発明において好ましく用いられるフエノー
ル法の1例は以下の通りである。
ウイルス感染細胞(3×105個)をリン酸緩
衝生理食塩水(PBS)で一度洗浄し、1500rpm
で5分間遠心して得られた細胞を0.1Mエチレ
ンジアミンテトラ酢酸と1.0%のドデシル硫酸
ナトリウムを含む0.05Mトリス塩酸緩衝液(PH
7.5)に懸濁させ、室温にて10分間放置する。
これに、プロナーゼを500μg/mlの割合で添
加し37℃で3時間処理し、更にこれに等容量の
フエノールを加え、充分に混和して後、
2000rpmで10分間遠心分離して水層に核酸を抽
出する(この操作を3回くり返す)。得られた
水層に酢酸ナトリウムを0.3Mとなるように加
える。その後、この溶液に氷冷下、冷却した2
〜2.5倍容量のエタノールを滴下し、−70℃で10
分間放置した後、15000rpmで5分間遠心して、
得られた沈殿を風乾する。そしてこの沈殿を、
0.015M塩化ナトリウム及び0.0015Mクエン酸
ナトリウムの水溶液に再懸濁し、これに100単
位/mlのRNase(予め90℃で10分間熱処理した
もの)を加え37℃で2時間処理し、混在してい
るRNAを分解して目的とする精製全DNAを得
る。
(2) ジエチルピロカーボネート法の1例は以下の
通りである。
前記(1)のフエノール法の場合と同様にして得
られた細胞を、1.0%のドデシル硫酸ナトリウ
ムと0.1〜0.5%のDEPCを含む0.05Mトリス塩
酸緩衝液(PH7.5)に懸濁させ、0℃で20分間
おだやかに撹拌する。その後等量のエチルエー
テルを加え、DEPCを除去した後、1500rpmで
3〜5分間遠心分離して得られた下層(水層)
に、酢酸ナトリウムを0.3Mとなる様に加える。
その後、得られた溶液に氷冷下、冷したエタ
ノールを滴下し、以後は前記(1)のフエノール法
の場合と同様に処理する。
本発明において用いられる制限酵素は、DNA
の特異的なヌクレオチド配列を認識し、特異的な
部位でDNAを切断する酵素であれば特に限定は
ない。これらは一般に型の制限酵素と呼ばれて
おり、例えば、BamH、Hind、EcoR、
Sal、Hpaがある。しかしながら、かかる制
限酵素によるDNAの切断パターンを個々のウイ
ルス血清型の型別同定に具体的に応用するために
は、特定のウイルスあるいは特定の血清型に合せ
て、実施例に述べる如き方法等で型の制限酵素
の中から最適のものを選択する必要がある。例え
ば、アデノウイルスDNAの血清型の型別同定を
行なうのに適した制限酵素は、まずアデノウイル
スDNAを分析可能な数の特異的フラグメントに
切断する制限酵素、例えば、6つの塩基配列を認
識するHind、EcoR、BamH、Sal及び
Hpaの中から選択を行なう。そして、更に、こ
れらの中から、異なる血清型間で共通の切断部位
のできるだけ少ない制限酵素を選択する必要があ
る。例えば、アデノウイルス3型と7型の切断パ
ターンは、Hind、EcoR又はSalを用いた
のでは明瞭に区別できないが、BamHの切断
パターンを比較すると明瞭に区別できる。従つ
て、アデノウイルスの3型と7型を区別するため
には、制限酵素としてBamHを用いるのが最
適であることがわかる。
以上の如き手法で、特定のウイルス血清型の型
別同定に最も適した制限酵素を、適宜選択するこ
とができる。
制限酵素によるDNAの切断と切断パターンの
作成は、例えば、下記の如き方法で行なうことが
できる(バイロロジー(Virology)第82巻、第
509−512頁、(1977)参照)。
DNAに対し充分量(例えば、DNA1μg当り
0.2〜1.0単位)の制限酵素を加え、37℃で3〜5
時間反応させる。反応液の総量は20〜70μと
し、適当な緩衝液を用いる。DNAの明瞭な切断
パターンを得るためには、0.4〜10μgのDNA量
で十分である。
反応終了後、反応液を、例えば1.4%アガロー
ス平板ゲルを用いて、泳動用緩衝液中で電気泳動
を行ない、エチジウムブロマイドで染色し、紫外
線下で切断パターンの観察、写真撮影を行なう。
制限酵素による切断パターンの比較は、サウザ
ーン(Southern)のブロツト法(J.MOl.Biol.、
98、503〜517(1975)参照)で行なうこともでき
る。即ち、前記の如く感染細胞DNAを制限酵素
で切断し、アガロースゲル電気泳動にかけ、アガ
ロースゲル中の各DNA断片をアルカリ処理によ
り一本鎖とした後、サウザーンの方法に従つてメ
ンブレンフイルター上に移し、 32P又は 3Hで標
識したブローベDNAとハイブリツドを形成させ
検出する。かかるサウザーンのブロツド法を利用
すると、切断パターンの比較検討に必要な感染細
胞DNA量は、より少なくすることができ、明瞭
な細胞変性効果が発現する前の感染細胞からも、
明瞭な切断パターンを得ることができる。
切断パターンの比較は、また、DBMペーパー
ブロツト法で行なうこともできる(Proc.Natl.
Acad.Sci.U.S.A.74、5350−5354参照)。即ち、ジ
アゾベンジルオキシメチル(DBM)で処理され
た3紙上にDNAを移し、 32P又は 3Hで標識し
たブローベDNAとハイブリツドを形成させて検
出する。
本発明の方法において、スポツトハイブリダイ
ゼーシヨン(Spot Hybridization)(Gann、70、
239〜243(1979)参照)法を併用することにより
DNAの制限酵素切断パターンによる同定がより
容易となる場合がある。例えば、アデノウイルス
感染細胞の全DNAをアルカリ処理後、メンブレ
ンフイルター上にスポツトし、 32Pで標識したア
デノウイルスの各亜群DNAとの間でハイブリツ
ドを形成させ、オートラジオグラフイホモロジー
の有無を検討し、あらかじめ感染ウイルスの亜群
を決定する。そして、その後は感染細胞全DNA
の切断パターンを同一の亜群内のDNAウイルス
の切断パターンと比較すればウイルス血清型の型
別が容易に同定できる。
本発明の方法によれば、少量のウイルス感染細
胞を用い(必要な感染細胞数は、精製ウイルスの
DNAを用いる場合の約1/40以下)、ウイルス
DNAと細胞DNAを分離することなく、簡単かつ
正確にウイルス血清型の型別の固定を行なうこと
ができるので、本発明は、ウイルス病の診断、治
療及び予防あるいはウイルスに関する医学研究上
その利用価値は極めて大きなものである。
以下、実施例により本発明を詳述する。
実施例 1
本実施例は、DNAウイルス感染細胞から全
DNAを抽出し、これをそのまゝ(ウイルスDNA
と細胞DNAに分離することなく)制限酵素で切
断しその切断パターンを作成すると、そこに形成
されるウイルスDNAの切断パターンは細胞DNA
の存在に影響を受けることなく、精製ウイルス
DNAを用いた場合と同一の切断パターンを示す
ことを例示するものである。
(1) DNAウイルス(アデノウイルス7型)感染
細胞の培養
KB細胞を直径3cmのシヤーレを用い、5%
子牛血清を含むイーグル ミニマム エツセン
シヤル メデイウム(MEM)で単層培養し
(細胞数約1.5×105個)、これにウイルスを
moi10−50PFU/cellで接種し、37℃で明瞭な
細胞変性効果が見られるまで約3日間培養し
た。
(2) ウイルス(アデノウイルス7型)DNAの抽
出・精製
グリーンとピナ(Green and Pina)の方法
に基づき(Proc.Natl.Acad.Sci.51、1251−
1259(1964)及びVirology20、199−207(1963)
参照)、前記(1)で得られた感染細胞を破壊し有
機溶媒で細胞由来蛋白を変性除去し、塩化セシ
ウム密度勾配平衡遠心によりウイルス粒子を精
製した。その後、フエノール法を適用してウイ
ルスDNAの抽出・精製を行なつた。
(3) 感染細胞の全DNAの抽出・精製
前記(1)で得られたDNAウイルス感染細胞を、
フエノール法に従つて処理し(フエノール処理
以降は2回くり返した)、感染細胞の全DNAの
抽出・精製を行なつた。
(4) 感染細胞の全DNAの制限酵素による切断と
切断パターン
前記(3)で得られた感染細胞の全DNAを10μ
gをとり、これに制限酵素としてDNA1μg当
りHind、BamH、Sal又はEcoRを充
分量加え、37℃で5時間反応させた。なお、反
応用緩衝液としては、Hindの場合は20m
MTris−HCl(PH7.4)、7mMMgCl2、60m
MNaCl、2mM2−メルカプトエタノールの系
を、BamHの場合は6mMTrisHCl(PH7.5)、
6mMMgCl2、20mMKCl、6mM2−メルカ
プトエタノールの系を、Salの場合は、50m
MTris−HCl(PH7.5)、10mMMgCl2の系を、
EcoRの場合は100mMTris−HCl(PH7.5)、
10mMMgCl2、50mMNaClの系を用い、反応
混液の総量は50μであつた。
反応終了後、反応混液を1.4%アガロース平
板ゲル(2×160×220mm)を用いて、泳動用緩
衝液−36mMTris−HCl(PH8.1)、32m
MKH2PO4、0.1mMEDTA中で、13時間、
50Vで電気泳動を行ない、エチジウムブロミド
(0.5μg/ml)で15分間染色し、染外線下で切
断パターンの観察と写真撮影を行なつた。用い
た制限酵素毎に、その切断パターンを第1図の
それぞれaとして示した。
上記と全く同様にして(但し、ウイルス
DNAは1μgを使用)、前記(2)で得られたウイ
ルスDNAのみの制限酵素切断パターンを求め、
第1図のbとして示した。
第1図から明らかな如く、感染細胞の全DNA
の切断パターン(a)において、その背景に細胞
DNAの連続的なパターンが薄く現われてはいる
が(第1図のaにおいて斜線で示した。なお第
2,3図では省略。)、これはウイルスの同定に障
害となる程のものではないことがわかる。そして
また、かくして形成されたウイルスDNAの切断
パターンは、精製ウイルスDNAの切断パターン
(b)と完全に一致していることがわかる。
以上の事実は、ウイルスDNAの制限酵素切断
パターンを調べるためには、感染細胞からウイル
ス粒子の単離・精製そしてウイルスDNAの抽
出・精製という煩雑な操作を行なつて試料を調製
する必要はなく、感染細胞から直接全DNAを抽
出精製し、それをそのまゝ試料として用いれば良
いことを示している。また、第1図から明らかな
如く、ウイルスの血清型は同じでも、用いる制限
酵素によつて切断パターンは異なるので、特定の
ウイルスの特定の血清型を同定するには、それに
最も適した制限酵素を選択するのが望ましい。
実施例 2
本実施例は、感染細胞の全DNAの制限酵素切
断パターンから、アデノウイルス3型と7型(共
にB群に属しDNAホモロジーが高い)の区別が
できることを示す例である。
ウイルスとしてそれぞれアデノウイルス3型と
7型を用い、実施例1の(1)(3)及び(4)の場合と同様
にして、各種制限酵素(Hind、BamH、Sal
、EcoR)の切断パターンを得た。その結果
を第2図に示した。
第2図から明らかな如く、アデノウイルス3型
と7型の切断パターンは、Hind、Sal及び
EcoRを用いた場合には酷似しており区別が困
難であるが、一方BamHを用いた場合には、
両者でバンドの数と位置が異なり明確に区別でき
る。
実施例 3
本実施例は、BamHを用いた場合、アデノ
ウイルスの各型によつて制限酵素切断パターンが
明瞭に異なることを示すものである。
アデノウイルスとしてそれぞれ12、31(以上A
群)、3、7(以上B群)、2、5(以上C群)、9、
13(以上D群)及び4(E群)の各型のウイルスを
用い、制限酵素としてBamHを用いて、実施
例(1)(3)及び(4)の場合と同様にして切断パターンを
得た。それらの結果を第3図に示した。第3図か
ら、12型は8本、31型は11本、3型は9本、7型
は9本、2型は4本、5型は2本、9型は4本、
13型は4本、4型は8本のバンドが明瞭に観察で
き、それぞれが区別できることがわかる。
次に、EcoRにより切断形成されたアデノウ
イルス7型のDNAフラグメント、Hindにより
切断形成された12型のDNAフラグメント及び
BamHにより切断形成された2型のDNAフラ
グメントをサイズマーカーとして用いて得られ
た、電気泳動におけるDNAフラグメントの相対
移動度と分子量(ダルトン)の関係曲線(第4
図)に基づいて、前記BamHを用いた場合の
アデノウイルス各種の各バンド(DNAフラグメ
ント)の分子量を算出し、その結果を第1表に示
した。
The present invention relates to a method for identifying virus serotypes. More specifically, the present invention is based on the restriction enzyme cleavage pattern of total DNA of DNA virus-infected cells.
The present invention relates to a method for identifying virus serotypes. In order to appropriately diagnose, treat and prevent diseases caused by viruses, it is necessary to accurately identify the serotype of the virus. For example, adenovirus group viruses are the causative agents of diseases such as acute febrile pharyngitis, acute respiratory tract disease, pharyngoconjunctival fever, epidemic keratoconjunctivitis, and pertussis-like syndrome; There is a type (viral DNA
For the appropriate diagnosis, treatment, and prevention of diseases, it is necessary to accurately identify the virus serotype. Traditionally, for the identification of serotypes of viruses, e.g. adenoviruses, complement fixation and immunofluorescence have been used to detect common antigens of adenoviruses, while hemagglutination inhibition and neutralization reactions have been used to detect common antigens of adenoviruses. has been used to determine types. However, in the identification based on the hemagglutination inhibition reaction and the neutralization reaction, cross-reactivity may be observed between the types, and therefore, there are cases in which the accuracy is questionable.
Furthermore, it was necessary to prepare antiserum for each type, which caused problems in terms of simplicity. Recently, a method of cutting herpesvirus DNA with restriction enzymes and identifying the serotype from the cut pattern has been introduced (The Journal of Infectious Diseases).
Infectious Diseases) Volume 138, No. 4, No. 488
−498 pages (1978)). However, in this method, the herpesvirus is isolated and purified, and purification of the virus requires a large amount of infected cells and a complicated method, which requires a great deal of time and effort. This method had practical problems, especially in terms of diagnosis and treatment. The present inventors conducted intensive research on a method to easily and accurately identify the serotype of a DNA virus using a small amount of infected cells, and as a result, extracted total DNA from DNA virus-infected cells and Well, if you cut it with a restriction enzyme to form a cut pattern (without separating the viral DNA and cellular DNA), the virus will be removed without being affected by the cellular DNA.
The present invention was achieved based on the discovery that DNA cleavage patterns can be clearly distinguished and the serotype can be easily and accurately identified. That is, the present invention involves infecting DNA virus-susceptible cells with a DNA virus, culturing the infected cells, extracting and purifying the total DNA of the infected cells, and then extracting and purifying the extracted and purified total DNA without separating the viral DNA and the cellular DNA. DNA is cut with restriction enzymes and the cut pattern is compared to DNA viruses of known serotypes.
This is a method for identifying virus serotypes, which is characterized by comparison with DNA restriction enzyme cleavage patterns. There are no particular restrictions on the DNA viruses whose serotypes can be identified using the method of the present invention, and the principle can be applied to any DNA virus, including adenovirus group viruses and herpes group viruses. It can be particularly suitably applied to. Any DNA virus-susceptible cell may be used as long as it can be infected with a DNA virus and multiply, but in the case of adenovirus group viruses, KB cells, Hela cells, and human fetal kidney cells are preferable; Hep in case of virus
Cells, Hela cells or Velo cells are preferred, and in the case of varicella virus among the herpes group viruses, human fetal lung cells and fibroblasts are more preferred. Infected cells infected with a DNA virus can be cultured by known methods. Suitable media include, for example, Eagle Minimum Essential Medium (MEM) containing 5% calf serum. As for the culture conditions, for example, 1 to 7 days at 37° C. under 5% CO 2 aeration is sufficient. If the infected cells are destroyed and virus particles are released, it will be inconvenient for subsequent treatment, so it is most preferable to stop the culture at the stage when a clear cytopathic effect appears. Subsequently, from such infected cells, the entire DNA of the infected cells, i.e. the viral DNA and the cell
Extract and purify DNA. The DNA extraction and purification method is not particularly limited, but the following phenol method and diethylpyrocarbonate (DEPC) method are preferred. The latter is particularly suitable when treating small amounts of cells. (1) An example of the phenol method preferably used in the present invention is as follows. Virus-infected cells (3 x 10 cells ) were washed once with phosphate buffered saline (PBS) and incubated at 1500 rpm.
Centrifuge the cells for 5 minutes at
7.5) and leave at room temperature for 10 minutes.
To this, pronase was added at a rate of 500 μg/ml and treated at 37°C for 3 hours, and then an equal volume of phenol was added and mixed thoroughly.
Centrifuge at 2000 rpm for 10 minutes to extract nucleic acids into the aqueous layer (repeat this operation 3 times). Add sodium acetate to the resulting aqueous layer to a concentration of 0.3M. Thereafter, this solution was cooled on ice with 2
Add ~2.5 times the volume of ethanol dropwise and incubate at −70°C for 10
After leaving for a minute, centrifuge at 15,000 rpm for 5 minutes,
The resulting precipitate is air-dried. And this precipitate,
Resuspend in an aqueous solution of 0.015M sodium chloride and 0.0015M sodium citrate, add 100 units/ml of RNase (previously heat-treated at 90°C for 10 minutes), and treat at 37°C for 2 hours. Decompose the RNA to obtain the desired purified total DNA. (2) An example of the diethylpyrocarbonate method is as follows. Cells obtained in the same manner as in the case of the phenol method in (1) above are suspended in 0.05M Tris-HCl buffer (PH7.5) containing 1.0% sodium dodecyl sulfate and 0.1 to 0.5% DEPC, Stir gently for 20 minutes at 0°C. After that, an equal amount of ethyl ether was added to remove DEPC, and the resulting lower layer (aqueous layer) was centrifuged at 1500 rpm for 3 to 5 minutes.
Add sodium acetate to 0.3M. Thereafter, cooled ethanol is added dropwise to the obtained solution under ice-cooling, and the subsequent treatment is carried out in the same manner as in the phenol method described in (1) above. The restriction enzyme used in the present invention is DNA
There is no particular limitation as long as it is an enzyme that recognizes a specific nucleotide sequence and cuts DNA at a specific site. These are commonly called type restriction enzymes, such as BamH, Hind, EcoR,
There are Sal and Hpa. However, in order to specifically apply the DNA cleavage pattern by such restriction enzymes to the identification of individual virus serotypes, methods such as those described in Examples may be used depending on the specific virus or specific serotype. It is necessary to select the most suitable restriction enzyme from among various types of restriction enzymes. For example, a restriction enzyme suitable for serotyping adenovirus DNA is a restriction enzyme that first cuts adenovirus DNA into an analyzable number of specific fragments, e.g., a restriction enzyme that recognizes a six-base sequence. Hind, EcoR, BamH, Sal and
Select from Hpa. Furthermore, it is necessary to select restriction enzymes from among these that have as few common cleavage sites as possible among different serotypes. For example, the cleavage patterns of adenovirus types 3 and 7 cannot be clearly distinguished using Hind, EcoR, or Sal, but can be clearly distinguished when the cleavage patterns of BamH are compared. Therefore, in order to distinguish between adenovirus types 3 and 7, it is found that BamH is optimally used as a restriction enzyme. By the method described above, the restriction enzyme most suitable for type identification of a specific virus serotype can be appropriately selected. Cutting DNA with restriction enzymes and creating a cut pattern can be carried out, for example, by the following method (Virology, Vol. 82, Vol.
(1977), pp. 509-512). Sufficient amount for DNA (e.g. per 1μg of DNA)
Add 3-5 units of restriction enzyme (0.2-1.0 units) at 37°C.
Allow time to react. The total volume of the reaction solution is 20-70μ, and an appropriate buffer is used. A DNA amount of 0.4 to 10 μg is sufficient to obtain a clear cut pattern of DNA. After the reaction is completed, the reaction solution is electrophoresed in a migration buffer using, for example, a 1.4% agarose plate gel, stained with ethidium bromide, and the cutting pattern is observed and photographed under ultraviolet light. Comparison of cleavage patterns by restriction enzymes was performed using Southern's blotting method (J.MOl.Biol.,
98, 503-517 (1975)). That is, infected cell DNA was cut with restriction enzymes as described above, subjected to agarose gel electrophoresis, each DNA fragment in the agarose gel was made into a single strand by alkaline treatment, and then transferred onto a membrane filter according to Southern's method. , 32P or 3H labeled probe DNA and hybridization is formed and detected. By using Southern's blotting method, the amount of infected cell DNA required for comparative examination of cleavage patterns can be reduced, and even from infected cells before clear cytopathic effects have appeared,
Clear cutting patterns can be obtained. Comparison of cutting patterns can also be performed by the DBM paper blot method (Proc. Natl.
Acad.Sci.USA74, 5350-5354). That is, DNA is transferred onto 3 paper treated with diazobenzyloxymethyl (DBM) and detected by forming a hybrid with probe DNA labeled with 32 P or 3 H. In the method of the present invention, spot hybridization (Gann, 70,
239-243 (1979)).
Identification based on DNA restriction enzyme cleavage patterns may be easier. For example, the total DNA of adenovirus-infected cells is treated with alkali, spotted on a membrane filter, and hybridized with 32 P-labeled adenovirus subgroup DNA to determine the presence or absence of homology by autoradiography. and determine the subgroup of the infecting virus in advance. After that, the infected cell's entire DNA
Virus serotypes can be easily identified by comparing the cleavage pattern of the virus with the cleavage patterns of DNA viruses within the same subgroup. According to the method of the present invention, a small number of virus-infected cells are used (the required number of infected cells is
(approximately 1/40 less than when using DNA), viruses
Since it is possible to easily and accurately fix virus serotypes without separating DNA from cellular DNA, the present invention has great utility in the diagnosis, treatment, and prevention of viral diseases, and in medical research related to viruses. is extremely large. Hereinafter, the present invention will be explained in detail with reference to Examples. Example 1 In this example, whole cells were isolated from DNA virus-infected cells.
Extract the DNA and use it as is (viral DNA
When cutting with a restriction enzyme (without separating into cellular DNA) and creating a cutting pattern, the resulting cutting pattern of viral DNA is similar to that of cellular DNA.
purified virus without being affected by the presence of
This exemplifies that the same cleavage pattern as in the case of using DNA is shown. (1) Culture of cells infected with DNA virus (adenovirus type 7) KB cells were cultured at 5%
Virus was cultured in a monolayer (approximately 1.5 x 10 cells) in Eagle Minimum Essential Medium (MEM) containing calf serum.
The cells were inoculated at a moi of 10-50 PFU/cell and cultured at 37°C for about 3 days until a clear cytopathic effect was observed. (2) Extraction and purification of virus (adenovirus type 7) DNA Based on the method of Green and Pina (Proc. Natl. Acad. Sci. 51, 1251-
1259 (1964) and Virology 20, 199-207 (1963)
), the infected cells obtained in (1) above were disrupted, cell-derived proteins were denatured and removed with an organic solvent, and virus particles were purified by cesium chloride density gradient equilibrium centrifugation. Thereafter, the phenol method was applied to extract and purify the viral DNA. (3) Extraction and purification of total DNA from infected cells The DNA virus-infected cells obtained in (1) above,
The cells were treated according to the phenol method (the phenol treatment was repeated twice), and the total DNA of the infected cells was extracted and purified. (4) Cutting the total DNA of infected cells with restriction enzymes and cutting pattern The total DNA of infected cells obtained in (3) above was diluted with 10μ
A sufficient amount of Hind, BamH, Sal or EcoR was added as a restriction enzyme per 1 μg of DNA, and the reaction was carried out at 37° C. for 5 hours. In addition, in the case of Hind, the reaction buffer is 20m
MTris-HCl (PH7.4), 7mM MgCl2 , 60m
MNaCl, 2mM2-mercaptoethanol system, in the case of BamH, 6mM TrisHCl (PH7.5),
A system of 6mM MgCl 2 , 20mM KCl, 6mM2-mercaptoethanol was added to
MTris-HCl (PH7.5), 10mMgCl2 system,
For EcoR, 100 mMTris-HCl (PH7.5),
A system of 10mM MgCl 2 and 50mM NaCl was used, and the total amount of the reaction mixture was 50μ. After the reaction, the reaction mixture was transferred to a 1.4% agarose plate gel (2 x 160 x 220 mm) using running buffer - 36mM Tris-HCl (PH8.1) for 32m
MKH 2 PO 4 in 0.1 m MEDTA for 13 hours;
Electrophoresis was performed at 50 V, and the cells were stained with ethidium bromide (0.5 μg/ml) for 15 minutes, and the cutting patterns were observed and photographed under external light. The cleavage pattern for each restriction enzyme used is shown as a in FIG. 1, respectively. Exactly the same way as above (but with the virus
(use 1 μg of DNA), determine the restriction enzyme cleavage pattern of only the viral DNA obtained in (2) above,
It is shown as b in FIG. As is clear from Figure 1, the total DNA of infected cells
In the cutting pattern (a), there are cells in the background.
Although a continuous pattern of DNA appears faintly (indicated by diagonal lines in a of Figure 1, omitted in Figures 2 and 3), this is not enough to hinder the identification of the virus. I understand that. And also, the cleavage pattern of the viral DNA thus formed is the cleavage pattern of the purified viral DNA.
It can be seen that this is completely consistent with (b). The above facts indicate that in order to investigate the restriction enzyme cleavage pattern of viral DNA, it is not necessary to prepare a sample by performing the complicated operations of isolating and purifying virus particles from infected cells and extracting and purifying the viral DNA. This shows that it is possible to directly extract and purify total DNA from infected cells and use it as a sample. Furthermore, as is clear from Figure 1, even if the serotype of the virus is the same, the cleavage pattern differs depending on the restriction enzyme used. Therefore, in order to identify a specific serotype of a specific virus, it is necessary to use the most suitable restriction enzyme. It is desirable to select . Example 2 This example shows that adenovirus types 3 and 7 (both belong to group B and have high DNA homology) can be distinguished from the restriction enzyme cleavage pattern of total DNA of infected cells. Adenovirus types 3 and 7 were used as viruses, and various restriction enzymes (Hind, BamH, Sal
, EcoR) was obtained. The results are shown in Figure 2. As is clear from Figure 2, the cleavage patterns of adenovirus types 3 and 7 are Hind, Sal and
When EcoR is used, they are very similar and difficult to distinguish, but on the other hand, when BamH is used,
The number and position of bands are different between the two, and they can be clearly distinguished. Example 3 This example shows that when BamH is used, the restriction enzyme cleavage pattern clearly differs depending on the type of adenovirus. As adenoviruses, 12 and 31 (more than A
Group), 3, 7 (Group B), 2, 5 (Group C), 9,
Cleavage patterns were obtained in the same manner as in Examples (1), (3) and (4) using viruses of each type 13 (group D) and 4 (group E) and BamH as the restriction enzyme. Ta. The results are shown in Figure 3. From Figure 3, 12 type has 8 pieces, 31 type has 11 pieces, 3 type has 9 pieces, 7 type has 9 pieces, 2 type has 4 pieces, 5 type has 2 pieces, 9 type has 4 pieces,
It can be seen that 4 bands for type 13 and 8 bands for type 4 can be clearly observed, and they can be distinguished from each other. Next, the adenovirus type 7 DNA fragment cut and formed by EcoR, the type 12 DNA fragment cut and formed by Hind, and
Relationship curve between relative mobility of DNA fragments in electrophoresis and molecular weight (daltons) obtained using type 2 DNA fragments cleaved by BamH as size markers (4th
The molecular weight of each band (DNA fragment) of each adenovirus was calculated based on the above-mentioned BamH, and the results are shown in Table 1.
【表】【table】
【表】
第1表より、各型により特異な制限酵素切断パ
ターンが数値として得られ、これは型別の同定に
利用できることがわかる。[Table] From Table 1, it can be seen that a unique restriction enzyme cleavage pattern for each type can be obtained as a numerical value, and this can be used for identification of each type.
第1図は、各種制限酵素(Hind、BamH、
Sal及びEcoR)によるアデノウイルス7型感
染細胞の全DNAの切断パターン(a)と、アデノウ
イルス7型DNAの切断パターン(b)を示す。第2
図は、各種制限酵素(Hind、BamH、Sal
及びEcoR)によるアデノウイルス3型感染細
胞の全DNAの切断パターンと、アデノウイルス
7型感染細胞の全DNAの切断パターンの比較を
示す。第3図は、制限酵素としてBamHを用
いた場合の、アデノウイルス各型感染細胞の全
DNA切断パターンを示す。第4図は、電気泳動
におけるDNAフラグメントの相対移動度と分子
量(ダルトン)の関係曲線を示す。
Figure 1 shows various restriction enzymes (Hind, BamH,
The cleavage pattern (a) of total DNA of adenovirus type 7-infected cells by Sal and EcoR) and the cleavage pattern of adenovirus type 7 DNA (b) are shown. Second
The figure shows various restriction enzymes (Hind, BamH, Sal
A comparison of the total DNA cleavage pattern of cells infected with adenovirus type 3 and the total DNA cleavage pattern of cells infected with adenovirus type 7 by adenovirus type 3 and EcoR) is shown. Figure 3 shows the total amount of cells infected with each type of adenovirus using BamH as a restriction enzyme.
Showing DNA cleavage patterns. FIG. 4 shows a relationship curve between relative mobility of DNA fragments in electrophoresis and molecular weight (Dalton).
Claims (1)
感染させ、この感染細胞を培養後感染細胞の全
DNAを抽出精製し、次いでウイルスDNAと細胞
DNAを分離することなく前記抽出精製した全
DNAを制限酵素で切断し、その切断パターンを、
血清型が既知のDNAウイルスのDNAの制限酵素
切断パターンと比較することを特徴とする、ウイ
ルス血清型の型別同定法。 2 DNAウイルス感受性細胞が、KB細胞、
Hela細胞、ヒト胎児腎細胞、又はVelo細胞であ
る、特許請求の範囲第1項記載のウイルス血清型
の型別同定法。 3 感染細胞の培養を、感染細胞の明瞭な細胞変
性効果が発現するまで行なう、特許請求の範囲第
1項記載のウイルス血清型の型別同定法。 4 制限酵素がBamH、Hind、EcoR、
Sal又はHpaである、特許請求の範囲第1項
記載のウイルス血清型の型別同定法。 5 制限酵素切断パターンが、電気泳動法による
切断パターンである、特許請求の範囲第1項記載
のウイルス血清型の型別同定法。 6 制限酵素切断パターンの比較が、エチジウム
ブロマイド染色法又はサウザーン(Southern)
のブロツト法又はDBMペーパーブロツト法によ
り行われる、特許請求の範囲第1項記載のウイル
ス血清型の型別同定法。[Claims] 1. Infect DNA virus-susceptible cells with a DNA virus, culture the infected cells, and then
DNA is extracted and purified, then viral DNA and cells
All the extracted and purified products without separating the DNA.
DNA is cut with a restriction enzyme, and the cut pattern is
A method for identifying virus serotypes, which is characterized by comparing the DNA restriction enzyme cleavage patterns of DNA viruses with known serotypes. 2 DNA virus-susceptible cells are KB cells,
The method for identifying virus serotypes according to claim 1, which is Hela cells, human fetal kidney cells, or Velo cells. 3. The method for identifying virus serotypes according to claim 1, wherein the infected cells are cultured until a clear cytopathic effect of the infected cells appears. 4 Restriction enzymes are BamH, Hind, EcoR,
The method for identifying a virus serotype according to claim 1, which is Sal or Hpa. 5. The method for identifying virus serotypes according to claim 1, wherein the restriction enzyme cleavage pattern is a cleavage pattern determined by electrophoresis. 6 Restriction enzyme cleavage patterns can be compared using ethidium bromide staining or Southern
The method for identifying virus serotypes according to claim 1, which is carried out by the DBM paper blotting method or the DBM paper blotting method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3954981A JPS57156422A (en) | 1981-03-20 | 1981-03-20 | Individual indentification of viral serotype |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3954981A JPS57156422A (en) | 1981-03-20 | 1981-03-20 | Individual indentification of viral serotype |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS57156422A JPS57156422A (en) | 1982-09-27 |
| JPS6363067B2 true JPS6363067B2 (en) | 1988-12-06 |
Family
ID=12556131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3954981A Granted JPS57156422A (en) | 1981-03-20 | 1981-03-20 | Individual indentification of viral serotype |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS57156422A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH041468U (en) * | 1990-04-19 | 1992-01-08 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4339352A1 (en) * | 1993-11-18 | 1995-05-24 | Univ Ludwigs Albert | Method for labeling cells, cells labeled with this method, use of the wild-type adeno-associated virus for labeling cells and test kits for detecting the wild-type adeno-associated virus in cells |
-
1981
- 1981-03-20 JP JP3954981A patent/JPS57156422A/en active Granted
Non-Patent Citations (1)
| Title |
|---|
| J.MOL.BIOL=1975 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH041468U (en) * | 1990-04-19 | 1992-01-08 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS57156422A (en) | 1982-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shatkin et al. | Separation of ten reovirus genome segments by polyacrylamide gel electrophoresis | |
| Lavi et al. | Persistence of mouse hepatitis virus A59 RNA in a slow virus demyelinating infection in mice as detected by in situ hybridization | |
| Dörries et al. | Progressive multifocal leucoencephalopathy: detection of papovavirus JC in kidney tissue | |
| Chinnadurai et al. | Physical mapping of a large-plaque mutation of adenovirus type 2 | |
| Kleiboeker et al. | Association of two newly recognized herpesviruses with interstitial pneumonia in donkeys (Equus asinus) | |
| Tenser et al. | Detection of herpes simplex virus mRNA in latently infected trigeminal ganglion neurons by in situ hybridization | |
| Carrillo et al. | Long-term persistent infection of swine monocytes/macrophages with African swine fever virus | |
| Chang et al. | Diversity (polymorphism) of the meq gene in the attenuated Marek's disease virus (MDV) serotype 1 and MDV-transformed cell lines | |
| Feldman et al. | Transcription of the genome of pseudorabies virus (a herpesvirus) is strictly controlled | |
| Brahic et al. | Detection of picornavirus sequences in nervous tissue of amyotrophic lateral sclerosis and control patients | |
| Ostrow et al. | Identification of a novel human papilloma virus in cutaneous warts of meathandlers | |
| Dubensky et al. | Detection of DNA and RNA virus genomes in organ systems of whole mice: patterns of mouse organ infection by polyomavirus | |
| Edvardsson et al. | Assembly intermediates among adenovirus type 5 temperature-sensitive mutants | |
| JP4472171B2 (en) | Oligonucleotides for the amplification and detection of Epstein-Barr virus (EBV) nucleic acids | |
| Spatz et al. | Sequence determination of a mildly virulent strain (CU-2) of Gallid herpesvirus type 2 using 454 pyrosequencing | |
| Takiff et al. | Detection of enteric adenoviruses by dot‐blot hybridization using a molecularly cloned viral DNA probe | |
| Burlingham et al. | An endonuclease in cells infected with adenovirus and associated with adenovirions | |
| WO1992014846A1 (en) | Method of type-specific detection of herpes simplex virus | |
| Marks et al. | Transcription in mouse embryo cells permissively infected by murine cytomegalovirus | |
| Wheeler et al. | Cell-free synthesis of polyoma virus capsid proteins VP1 and VP2 | |
| JPS6363067B2 (en) | ||
| Wang et al. | An adenovirus mRNA which encodes a 14,700-Mr protein that maps to the last open reading frame of region E3 is expressed during infection | |
| Willcocks et al. | Restriction enzyme analysis of faecal adenoviruses in Newcastle upon Tyne | |
| Brusca et al. | Transforming genes among three different oncogenic subgroups of human adenoviruses have similar replicative functions | |
| Gissmann et al. | Physical characterization of the deoxyribonucleic acids of different human papilloma viruses (HPV) |